Bristol-Myers Squibb (BMY) Releases Quarterly Earnings Results
Bristol-Myers Squibb (NYSE:BMY) posted its quarterly earnings results on Wednesday. The company reported $0.46 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.02, Analyst Ratings Network.com reports. The company had revenue of $4.07 billion for the quarter, compared to the consensus estimate of $4.02 billion.
Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 49.73 on Wednesday. Bristol-Myers Squibb has a 52 week low of $30.64 and a 52 week high of $49.57. The stock has a 50-day moving average of $42.73 and a 200-day moving average of $42.60. The company has a market cap of $81.872 billion and a price-to-earnings ratio of 60.72.
The company also recently announced a quarterly dividend, which is scheduled for Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Wednesday, October 2nd.
A number of research firms have recently commented on BMY. Analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note to investors on Friday, October 18th. On a related note, analysts at Jefferies Group reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research note to investors on Friday, October 11th. Finally, analysts at Zacks upgraded shares of Bristol-Myers Squibb from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, October 9th. They now have a $49.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $47.80.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.